‘Arimidex’ (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview
- 30 September 2003
- journal article
- clinical trial
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 86 (3-5), 399-403
- https://doi.org/10.1016/s0960-0760(03)00350-9
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized TrialJournal of Clinical Oncology, 2000
- Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinomaCancer, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinomaCancer, 1997
- A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *European Journal Of Cancer, 1996
- Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancerBritish Journal of Cancer, 1988
- CONTROLLED TRIAL OF TAMOXIFEN AS SINGLE ADJUVANT AGENT IN MANAGEMENT OF EARLY BREAST CANCER: Analysis at Six Years by Nolvadex Adjuvant Trial OrganisationThe Lancet, 1985
- CONTROLLED TRIAL OF TAMOXIFEN AS ADJUVANT AGENT IN MANAGEMENT OF EARLY BREAST CANCERThe Lancet, 1983